Blood Compatibility of Cetyl Alcohol/Polysorbate-Based Nanoparticles

摘要: Pegylated and nonpegylated cetyl alcohol/polysorbate nanoparticles (E78 NPs) are being tested as drug carriers for specific tumor brain targeting. Because these nanoparticle formulations designed systemic administration, it is important to test the compatibility of lipid-based NPs with blood cells. The hemocompatibility E78 was evaluated a particular focus on hemolytic activity, platelet function, coagulation. Human red cell lysis determined by measuring hemoglobin release. Activation aggregation human platelets were using flow cytometry aggregometry, respectively. Finally, whole clotting time measured blood. did not cause in vitro at concentrations up 1 mg/mL. In addition, under conditions tested, polyethylene glycol (PEG)-coated (PEG-E78 activate platelets. fact, both NP very rapidly inhibited agonist-induced activation dose-dependent manner. Additionally, significantly prolonged concentration 500 μg/mL or greater. It concluded that PEG-coated have potential clinically relevant doses. Based calculated nanoparticle-to-platelet ratio, which could potentially affect function vivo approximately 1 mg/mL.